PHVS
Live chart
What they do
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema.
For information only · Important disclosures
Grades vs sector
No sector grades for PHVS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | -0.65 | -0.70 | -7.1% |
| 2026-04-02 | -0.62 | -0.71 | -15.4% |
| 2025-11-12 | -0.67 | -0.60 | +10.7% |
| 2025-08-12 | -0.77 | -0.83 | -8.5% |
| 2025-05-13 | -0.83 | -0.85 | -2.8% |
| 2025-04-07 | -0.73 | -0.64 | +11.9% |
| 2024-11-13 | -0.60 | -0.77 | -27.4% |
| 2024-08-14 | -0.58 | -0.55 | +4.8% |
Insider trades
$395.5K
$29.0K
$218.8K
$765.5K
$558.8K
$2.0M
$7.0M
$3.5M
$237.4K
$331.7K
$54.9K
$1.7M
Stats refreshed 2026-10-21 17:58:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026